MaxCyte Inc (NASDAQ:MXCT) is set to release its Q2 2025 earnings on August 6, 2025. The consensus estimate for Q2 2025 revenue is $9.57 million, and the earnings are expected to come in at -$0.10 per ...

An announcement from MaxCyte ( (MXCT)) is now available. On May 12, 2026, MaxCyte reported first-quarter 2026 revenue of $9.7 million, down 7% year on year, with core business revenue falling 25% to ...

MaxCyte, Inc. has announced preliminary financial results for the fourth quarter and full year of 2024, projecting core revenue between $8.3 million and $8.5 million for the fourth quarter, up from $7 ...

MaxCyte, Inc. has announced the acquisition of SeQure Dx, a company specializing in assessing on-target and off-target gene editing for cell and gene therapies. This strategic move enhances MaxCyte's ...

A look at the shareholders of MaxCyte, Inc. (LON:MXCT) can tell us which group is most powerful. With 66% stake, institutions possess the maximum shares in the company. That is, the group stands to ...

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement. Full year 2025 revenue of $33.0 million, at the top of the range of ...

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...

MaxCyte's fourth quarter and full year results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte's quarterly and year-end closing processes and review ...